Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096418 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
A Phase 4 study of Breast Neoplasm Female, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03096418 is a Phase 4 study of Breast Neoplasm Female that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 50 participants, below the 174-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03096418, a Phase 4 study of Breast Neoplasm Female, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Conditions Studied
Interventions
- DRUG Paclitaxel
Study Locations (2)
Iowa
- University of Iowa Health Care/Holden Comprehensive Cancer Center - Iowa City
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03096418
The ClinicalTrials.gov registry entry for NCT03096418 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (71% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel is the first listed.
NCT03096418 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Iowa, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03096418 about?
NCT03096418 is a clinical study titled "Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response". The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day ...
What is the current status of trial NCT03096418?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2017-03-13. Estimated completion is 2026-06.
What conditions does trial NCT03096418 study?
This clinical trial studies the following conditions: Breast Neoplasm Female.
What interventions are being tested in trial NCT03096418?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03096418?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03096418 being conducted?
This trial has 2 study locations across Iowa, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
RECRUITING · NA
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
ACTIVE NOT RECRUITING · Phase 2
-
Study on Physical Activity's Relationship With Cancer and Cognition
COMPLETED · NA
-
Web-Base App To Improve Aromatase Inhibitor Adherence
COMPLETED · NA
-
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.